<p>OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - 获取免费报告) 在 12 月份的空头头寸大幅增长。截至 12 月 15 日，空头头寸总计为 69,191 股，比 11 月 30 日的 19,869 股增长了 248.2%。大约 0.3% 的公司股份被卖空。根据平均交易量 200,019 股，当前的空头头寸比率为 0.3 天。</p>
<h2>OKYO Pharma 股价上涨 2.9%</h2>
<p>周四中午交易中，NASDAQ OKYO 的股价上涨了 0.06 美元，达到 2.12 美元。该公司股票的交易量为 21,415 股，而其平均交易量为 142,311 股。OKYO Pharma 的 12 个月低点为 0.90 美元，12 个月高点为 3.35 美元。该公司的 50 日简单移动平均为 2.21 美元，200 日简单移动平均为 2.37 美元。</p>
<h2>分析师评级调整</h2>
<p>几位研究分析师最近对 OKYO 股票发布了报告。HC Wainwright 在 9 月 23 日的研究报告中重申了 “买入” 评级，并对 OKYO Pharma 的股票设定了 7.00 美元的目标价。B. Riley 在 12 月 8 日的报告中开始覆盖 OKYO Pharma，设定了 “买入” 评级和 5.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 OKYO Pharma 股票的 “卖出（d-）” 评级。最后，Zacks Research 在 9 月 16 日的研究报告中将 OKYO Pharma 的股票评级上调至 “持有”。两位投资分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，OKYO Pharma 目前的平均评级为 “持有”，共识目标价为 6.00 美元。</p>
<p><strong>查看我们对 OKYO 的最新股票分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>一家对冲基金最近在 OKYO Pharma 股票中购买了新股份。根据该公司在最近向证券交易委员会（SEC）提交的 13F 表格，财富增强顾问服务公司在第二季度收购了 OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - 免费报告) 的新股份。该机构投资者购买了 10,000 股公司股票，价值约 28,000 美元。2.97% 的股票由机构投资者持有。</p>
<h2>OKYO Pharma 公司简介</h2>
<p>(获取免费报告)</p>
<p>Okyo Pharma Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗炎症和纤维化疾病的新疗法。公司的产品线基于专有的 Fc 融合技术，旨在调节与糖尿病肾病和慢性移植物抗宿主病等疾病相关的免疫反应。Okyo Pharma 旨在通过针对与组织炎症和纤维化相关的关键细胞因子通路，解决重大的未满足医疗需求。</p>
<p>Okyo Pharma 的主要产品候选药物 OK-101 是一种 Fc 融合蛋白，目前正在进行糖尿病肾病的二期开发。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 OKYO Pharma 更好</li>
<li>请勿删除，立即阅读</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘记 AI，这将是下一个重大科技突破</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 OKYO Pharma 吗？</h2>
<p>在你考虑 OKYO Pharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 OKYO Pharma 并不在名单上。</p>
<p>虽然 OKYO Pharma 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OKYO

<p>OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) 在 12 月份的空头头寸增加了 248.2%，总计达到 69,191 股。根据平均交易量 200,019 股，空头头寸比率为 0.3 天。该股票上涨了 2.9%，报 2.12 美元，过去十二个月的价格区间为 0.90 美元至 3.35 美元。分析师的评级意见不一，普遍目标价为 6.00 美元。机构投资者持有该股票的 2.97%，一家对冲基金最近收购了 10,000 股</p>

<p>OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 69,191 shares, a growth of 248.2% from the November 30th total of 19,869 shares. Approximately 0.3% of the company's shares are sold short. Based on an average trading volume of 200,019 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 200,019 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the company's shares are sold short.</p>
<div class="lb-trans"><p>OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - 获取免费报告) 在 12 月份的空头头寸大幅增长。截至 12 月 15 日，空头头寸总计为 69,191 股，比 11 月 30 日的 19,869 股增长了 248.2%。大约 0.3% 的公司股份被卖空。根据平均交易量 200,019 股，当前的空头头寸比率为 0.3 天。</p>
</div><h2>OKYO Pharma Trading Up 2.9%</h2>
<div class="lb-trans"><h2>OKYO Pharma 股价上涨 2.9%</h2>
</div><p>Shares of NASDAQ OKYO traded up $0.06 during mid-day trading on Thursday, reaching $2.12. 21,415 shares of the company's stock were exchanged, compared to its average volume of 142,311. OKYO Pharma has a twelve month low of $0.90 and a twelve month high of $3.35. The business has a fifty day simple moving average of $2.21 and a 200 day simple moving average of $2.37.</p>
<div class="lb-trans"><p>周四中午交易中，NASDAQ OKYO 的股价上涨了 0.06 美元，达到 2.12 美元。该公司股票的交易量为 21,415 股，而其平均交易量为 142,311 股。OKYO Pharma 的 12 个月低点为 0.90 美元，12 个月高点为 3.35 美元。该公司的 50 日简单移动平均为 2.21 美元，200 日简单移动平均为 2.37 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several research analysts have recently issued reports on OKYO shares. HC Wainwright restated a &#34;buy&#34; rating and issued a $7.00 price target on shares of OKYO Pharma in a research report on Tuesday, September 23rd. B. Riley began coverage on OKYO Pharma in a report on Monday, December 8th. They set a &#34;buy&#34; rating and a $5.00 target price on the stock. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of OKYO Pharma in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded shares of OKYO Pharma to a &#34;hold&#34; rating in a research report on Tuesday, September 16th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, OKYO Pharma currently has an average rating of &#34;Hold&#34; and a consensus price target of $6.00.</p>
<div class="lb-trans"><p>几位研究分析师最近对 OKYO 股票发布了报告。HC Wainwright 在 9 月 23 日的研究报告中重申了 “买入” 评级，并对 OKYO Pharma 的股票设定了 7.00 美元的目标价。B. Riley 在 12 月 8 日的报告中开始覆盖 OKYO Pharma，设定了 “买入” 评级和 5.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 OKYO Pharma 股票的 “卖出（d-）” 评级。最后，Zacks Research 在 9 月 16 日的研究报告中将 OKYO Pharma 的股票评级上调至 “持有”。两位投资分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，OKYO Pharma 目前的平均评级为 “持有”，共识目标价为 6.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on OKYO</strong></p>
<div class="lb-trans"><p><strong>查看我们对 OKYO 的最新股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A hedge fund recently bought a new stake in OKYO Pharma stock. Wealth Enhancement Advisory Services LLC acquired a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company's stock, valued at approximately $28,000. 2.97% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一家对冲基金最近在 OKYO Pharma 股票中购买了新股份。根据该公司在最近向证券交易委员会（SEC）提交的 13F 表格，财富增强顾问服务公司在第二季度收购了 OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - 免费报告) 的新股份。该机构投资者购买了 10,000 股公司股票，价值约 28,000 美元。2.97% 的股票由机构投资者持有。</p>
</div><h2>OKYO Pharma Company Profile</h2>
<div class="lb-trans"><h2>OKYO Pharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company's pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.</p>
<div class="lb-trans"><p>Okyo Pharma Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗炎症和纤维化疾病的新疗法。公司的产品线基于专有的 Fc 融合技术，旨在调节与糖尿病肾病和慢性移植物抗宿主病等疾病相关的免疫反应。Okyo Pharma 旨在通过针对与组织炎症和纤维化相关的关键细胞因子通路，解决重大的未满足医疗需求。</p>
</div><p>Okyo Pharma's lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.</p>
<div class="lb-trans"><p>Okyo Pharma 的主要产品候选药物 OK-101 是一种 Fc 融合蛋白，目前正在进行糖尿病肾病的二期开发。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than OKYO Pharma</li>
<li>Do not delete, read immediately</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 OKYO Pharma 更好</li>
<li>请勿删除，立即阅读</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘记 AI，这将是下一个重大科技突破</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OKYO Pharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 OKYO Pharma 吗？</h2>
</div><p>Before you consider OKYO Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 OKYO Pharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 OKYO Pharma 并不在名单上。</p>
</div><p>While OKYO Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 OKYO Pharma 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

OKYO Pharma Limited 赞助的美国存托凭证（NASDAQ: OKYO）空头头寸更新